One of the most common questions we are asked at Denvax is not “how does immunotherapy work?” but something more direct and urgent: “Can it work for me?”

It is the right question to ask. Immunotherapy is a genuinely exciting development in cancer treatment, but it is not a one-size-fits-all solution. Whether it is appropriate for a specific patient depends on several factors — and understanding those factors is the first step toward making an informed decision about your treatment.

This guide will walk you through who is a good candidate for immunotherapy, what the evaluation process looks like, which cancer types respond particularly well, and what red flags to watch for in centres that promise results indiscriminately.

Why Immunotherapy Does Not Work for Everyone

Immunotherapy works by engaging the immune system to fight cancer. That means, for it to work, two things need to be true: your immune system must have sufficient capacity to mount a response, and your cancer must have features that make it recognisable or targetable by the immune system.

When either of those conditions is not met, immunotherapy may produce a weak response or none at all. This is not a failure of the patient — it is biology. Understanding this upfront protects patients from investing in a treatment that is unlikely to help their specific situation.

At Denvax, we evaluate every patient before recommending immunotherapy. If we do not believe immunotherapy is the right approach for someone, we say so. We would rather give you an honest answer than take you on as a patient who is unlikely to benefit.

Factors That Make Someone a Good Candidate for Immunotherapy

1. Cancer Type

Some cancers have substantially stronger evidence for immunotherapy response than others. Strong responders include:

– Melanoma — Immunotherapy has transformed outcomes in metastatic melanoma
– Non-small cell lung cancer (NSCLC) — Particularly in patients with high PD-L1 expression
– Bladder cancer — Checkpoint inhibitors are now first-line for advanced bladder cancer
– Kidney cancer (renal cell carcinoma) — High response rates with combination immunotherapy
– Head and neck cancers — Strong evidence for checkpoint inhibitor use
– Colorectal cancer with MSI-H/dMMR status — Microsatellite instability-high tumours respond very well
– Cervical cancer — Immunotherapy now indicated for advanced cervical cancer
– Hodgkin’s lymphoma — Among the strongest immunotherapy response rates of any cancer

Cancers where evidence is growing but more variable include breast cancer, gastric cancer, liver cancer, and pancreatic cancer. We still see meaningful responses in these cancers, particularly with Dendritic Cell Therapy, but expectations should be calibrated to what the evidence currently supports.

2. Biomarker Profile

Specific biomarkers in the tumour predict immunotherapy response. The most commonly tested are:

PD-L1 expression: Higher PD-L1 expression on tumour cells generally predicts better response to checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab). A pathology lab can test for this from a tissue biopsy sample.

Tumour Mutational Burden (TMB): Tumours with more mutations present more abnormal proteins (neoantigens) on their surface, making them more visible to the immune system. High-TMB tumours tend to respond better to immunotherapy.

Microsatellite Instability (MSI) and Mismatch Repair Deficiency (dMMR): Tumours with MSI-H (microsatellite instability-high) or dMMR (deficient mismatch repair) are highly responsive to immunotherapy across many cancer types. This is one of the strongest predictors of response currently available.

Specific mutation status: For Dendritic Cell Therapy specifically, we use antigens derived from your tumour to educate dendritic cells — so the therapy is not dependent on a single biomarker but rather the overall antigenic profile of your tumour.

3. Immune System Status

Immunotherapy requires an immune system capable of responding. Factors that affect immune status:

Prior treatment history: Heavy prior chemotherapy, particularly regimens that are significantly myelosuppressive (bone marrow suppressing), can reduce immune function. We assess blood counts and immune cell levels before initiating treatment.

Steroid use: Patients on long-term systemic corticosteroids have suppressed immune function. Tapering steroids prior to immunotherapy is usually required.

Autoimmune conditions: Pre-existing autoimmune diseases (rheumatoid arthritis, lupus, inflammatory bowel disease, etc.) require careful consideration. Immunotherapy can sometimes exacerbate autoimmune conditions. This does not automatically disqualify a patient but requires a carefully designed protocol.

HIV or other immunodeficiency states: These are evaluated individually.

4. Performance Status and Overall Health

Patients who are severely debilitated — very poor nutritional status, significant organ dysfunction, extremely low performance status — may not tolerate treatment well or may not benefit. We evaluate using standard performance status scales (ECOG or Karnofsky) and assess organ function through blood tests.

5. Stage of Cancer

Immunotherapy can be appropriate at all stages, but the approach differs:

Early stage: Immunotherapy may be used adjuvantly (after surgery or radiation) to reduce recurrence risk or perioperatively to improve surgical outcomes.

Locally advanced (Stage 3): Immunotherapy is increasingly used as part of multimodal treatment alongside chemotherapy or radiation.

Metastatic (Stage 4): Immunotherapy often represents the best available systemic treatment option, particularly when chemotherapy has failed or is poorly tolerated.

Who May Not Be a Suitable Candidate?

We will tell you honestly when immunotherapy is unlikely to be the right approach:

– Tumours with very low antigenicity — some cancers present very few identifiable markers that the immune system can target
– Severely immunosuppressed patients — where the immune system cannot mount a meaningful response
– Certain rapidly progressing tumours — where the time required to build an immune response is a concern and more immediate cytotoxic treatment is needed
– Patients with specific active autoimmune conditions — that checkpoint inhibitor therapy would significantly worsen

Being told you are not a candidate for one type of immunotherapy does not mean no immunotherapy is appropriate — for example, a patient who cannot receive checkpoint inhibitors may still benefit from Dendritic Cell Therapy, or vice versa. The evaluation is about which specific approach fits your specific situation.

The Evaluation Process at Denvax

If you come to Denvax to understand whether immunotherapy is appropriate for you, here is what the process looks like:

Initial Consultation (1–2 hours)
Dr. Khan and Dr. Yaqin review all your existing medical records, pathology reports, imaging (CT, PET, MRI), and treatment history. We take a detailed history and conduct a clinical assessment. We ask about your current medications, overall health, symptoms, and what outcomes are most important to you.

Biomarker Testing
If not already done, we recommend specific blood tests and, where appropriate, tissue biomarker testing (PD-L1, MSI, TMB). In some cases, we request additional imaging.

Multidisciplinary Review
Complex cases are reviewed with our broader team before a treatment recommendation is made.

Treatment Discussion
We present our assessment honestly. If immunotherapy is appropriate, we explain which approach, why, what the protocol looks like, expected timeline for response, side effects, and cost. If immunotherapy is not the best option, we explain why and what alternatives may be worth considering.

We do not push patients toward treatment they do not need. We do not promise outcomes we cannot guarantee. We do give you the most complete, honest picture we can.

How to Prepare for Your Consultation?

To make the most of your initial consultation at Denvax, bring:

– All recent pathology reports, biopsy reports, and histology findings
– Recent imaging reports and, if possible, the actual images (CD or digital files)
– A list of all current medications including supplements
– Records of any previous cancer treatment (chemotherapy protocols, radiation treatment records)
– A list of your questions — write them down before you come so nothing gets forgotten

You are welcome to bring a family member or caregiver. For many patients, having support in the room helps them retain information and make decisions more confidently.

Frequently Asked Questions

Q: I have already had chemotherapy that did not work. Can I still try immunotherapy?
A: In many cases, yes. Immunotherapy and chemotherapy work through entirely different mechanisms, so prior chemotherapy failure does not predict immunotherapy failure. However, we will assess whether your immune system has sufficient capacity after prior treatment. This is one of the evaluations we conduct at your initial consultation.

Q: Can immunotherapy work as a first treatment, before trying chemotherapy?
A: Absolutely. For many cancer types, immunotherapy is now recommended as a first-line treatment — not a last resort. In fact, starting immunotherapy when the immune system is still intact (before heavy chemotherapy) often produces the best results. If you have been recently diagnosed and are weighing treatment options, we encourage you to consult with us early.

Q: Does the success of immunotherapy depend on the stage of cancer?
A: Stage affects the goals of treatment — cure, long-term control, or quality of life management — but patients at every stage can benefit. Stage 4 patients can experience significant tumour reduction and extended survival. Stage 1–2 patients can use immunotherapy adjuvantly to reduce recurrence risk.

Q: How do I know if my cancer is immunogenic (responsive to immunotherapy)?
A: Biomarker testing is the most reliable way to assess this. PD-L1 testing, MSI testing, and TMB measurement are the most commonly used markers. A comprehensive pathology report from your tumour biopsy is a good starting point. At Denvax, we review these markers as part of your initial evaluation.

Q: My oncologist has not recommended immunotherapy — should I still consult Denvax?
A: Getting a second opinion is always your right as a patient, and we encourage it. Oncology is rapidly evolving and not every oncologist has the same depth of experience with immunotherapy. At Denvax, immunotherapy is our speciality. We will give you our honest assessment, which you can discuss with your existing oncologist.

Q: Is immunotherapy available for children with cancer?
A: Paediatric oncology with immunotherapy is an area of active development. Some immunotherapy approaches are approved for specific childhood cancers. We evaluate paediatric cases on an individual basis. Please contact us to discuss your child’s specific situation.

Find Out Whether Immunotherapy Is Right for You

The best way to know whether immunotherapy is appropriate for your situation is to speak with us directly. Our initial consultation is a genuine clinical assessment — not a sales conversation. We will review your case thoroughly and give you an honest answer.

Book a Consultation at Denvax →